Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
Cogent Biosciences (COGT) Stock Price & Analysis
523 Followers
COGT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.67 - $13.36
Previous Close$8.94
Volume822.69K
Average Volume (3M)1.37M
Market Cap
$854.78M
Enterprise Value$437.57M
Total Cash (Recent Filing)$435.74M
Total Debt (Recent Filing)$18.52M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 12, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding95,613,396
10 Day Avg. Volume1,883,269
30 Day Avg. Volume1,372,478
Standard Deviation0.67
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)4.25
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue460.60
Enterprise Value/Gross Profit460.60
Enterprise Value/Ebitda-2.54
Forecast
1Y Price Target
$16.44Price Target Upside99.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Cogent Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCOGT's bezu + suni combo achieved 19.4 months median progression-free survival in six second-line GIST patients, significantly surpassing historical results with suni monotherapy.
Regulatory AlignmentCOGT achieved FDA alignment on using its proprietary outcome measure as the primary endpoint of the pivotal SUMMIT Part 2 trial, easing investor concerns.
Safety And EfficacyThe safety of Bezuclastinib + Sunitinib combo does not appear to add severity to adverse events associated with Sunitinib monotherapy, offering an optimal safety profile.
Bears Say
CompetitivenessBezuclastinib's safety profile continues to look slightly worse than that of Ayvakit with issues like nausea, diarrhea, hair color changes and taste disorder.
Financial PerformanceCogent Therapeutics recorded a net loss of $0.62 per share—moderately wider than the previously forecasted net loss of $0.55 per share.
Market ShareWith some confounding data points and no clear differentiation versus the approved competitor, bezuclastinib is not expected to get higher than a ~25% share of the ISM market.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $3.67 and its highest was $13.36 in the past 12 months.
What is Cogent Biosciences’s market cap?
Currently, no data Available
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is Aug 12, 2024 which is in 40 days.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on May 07, 2024. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.515 by -$0.105.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -$0.56.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 95,613,396 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.515. Following the earnings report the stock price went up 2.51%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Among the largest hedge funds holding Cogent Biosciences’s share is Fairmount Funds Management Llc. It holds Cogent Biosciences’s shares valued at 32M.
---
Cogent Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.44 (99.51% Upside)
$16.44 (99.51% Upside)
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.49%
12-Months-Change
Fundamentals
Return on Equity
-65.70%
Trailing 12-Months
Asset Growth
80.89%
Trailing 12-Months
Company Description
Cogent Biosciences
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
---
COGT Stock 12 Month Forecast
Average Price Target
$16.44
▲(99.51% Upside)
Technical Analysis
Adverum Biotechnologies
―
Arvinas Holding Company
―
BioMarin Pharmaceutical
―
Alnylam Pharma
―
Best Analysts Covering COGT
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+10.76%
assigned a buy rating last month
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +10.76% per trade.
---